Ask AI
ProCE Banner Activity

CaDAnCe-101 Update: Phase I Study Evaluating BTK Degrader BGB-16673 in R/R CLL/SLL

Conference Coverage
Slideset

In this updated analysis from a phase I trial, the BTK protein degrader BGB-16673 was well tolerated in patients with heavily pretreated R/R CLL/SLL and demonstrated antitumor activity, including in patients with BTK mutations and those previously treated with covalent and noncovalent BTK inhibitors and BCL2 inhibitors.

Released: December 18, 2025

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Target Audience

This activity is intended for hematologists, oncologists, and other healthcare professionals caring for patients with relapsed/refractory CLL globally.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply recently presented data to clinical practice to expand treatment options and enhance outcomes for patients with relapsed/refractory CLL

  • Appraise the potential clinical implications of new data on novel targeted and cellular therapies for treatment selection and sequencing in patients with relapsed/refractory CLL

  • Support effective shared decision-making through patient education and resources on the potential clinical implications of recently presented data for relapsed/refractory CLL